N-氯乙酰氨基甲酸 | 6092-47-3

• 物质功能分类: 化学试剂 - 有机试剂 - 卤代脂肪烃
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-氯乙酰氨基甲酸
• 英文名称: ethyl (chloroacetyl)carbamate
• 英文别名: ethyl (2-chloroacetyl)-carbamate；ethyl N-(2-chloroacetyl)carbamate
• CAS: 6092-47-3
• 化学式: C₅H₈ClNO₃
• mdl: MFCD00800542
• 分子量: 165.576
• InChiKey: WMKXMEBGSGFRMT-UHFFFAOYSA-N

物化性质

• 熔点：
  126-131 °C
• 密度：
  1.3761 (rough estimate)
• 稳定性/保质期：
  <p><span style="FONT-SIZE: 9pt; FONT-FAMILY: 宋体; mso-font-kerning: 1.0pt; mso-bidi-font-family: Arial; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA"></span></p>

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 安全说明：
  S36,S36/37,S37
• 危险类别码：
  R21/22
• 海关编码：
  2924199090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P201,P202,P261,P264,P270,P271,P280,P302+P352,P304+P340,P308+P313,P310,P330,P361,P403+P233,P405,P501
• 危险品运输编号：
  2811
• 危险性描述：
  H301,H311,H331,H341
• 储存条件：
  密封储存，应存放在阴凉、干燥的库房中。

SDS

Name:	N-Chloroacetyl Urethane, 98% Material Safety Data Sheet
Synonym:	None.
CAS:	6092-47-3

Section 1 - Chemical Product MSDS Name: N-Chloroacetyl Urethane, 98% Material Safety Data Sheet
Synonym: None.

---

SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
6092-47-3	N-Chloroacetyl Urethane	98%	unlisted

Hazard Symbols: XN
Risk Phrases: 21/22

---

SECTION 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Harmful in contact with skin and if swallowed.The toxicological properties of this material have not been fully investigated. Potential Health Effects
Eye:
May cause eye irritation. The toxicological properties of this material have not been fully investigated.
Skin:
May cause skin irritation. The toxicological properties of this material have not been fully investigated.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

SECTION 4 - FIRST AID MEASURES
Eyes:
Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

SECTION 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

SECTION 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions. Provide ventilation.

---

SECTION 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 6092-47-3: Personal Protective Equipment
Eyes:
Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Physical State: Solid
Color: Not available.
Odor: Slightly irritating
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 129 - 132 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: soluble in alcohol, acetone
Specific Gravity/Density:
Molecular Formula: C5H8ClNO3
Molecular Weight: 165.58

---

SECTION 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, oxides of nitrogen, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

SECTION 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 6092-47-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
N-Chloroacetyl Urethane - Not listed by ACGIH, IARC, or NTP.

---

SECTION 12 - ECOLOGICAL INFORMATION

---

SECTION 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations.

---

SECTION 14 - TRANSPORT INFORMATION IATA Not regulated as a hazardous material. IMO Not regulated as a hazardous material. RID/ADR Not regulated as a hazardous material.

---

SECTION 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 21/22 Harmful in contact with skin and if swallowed.
Safety Phrases:
S 28A After contact with skin, wash immediately with plenty of water. S 36/37 Wear suitable protective clothing and gloves. S 37 Wear suitable gloves. S 45 In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). WGK (Water Danger/Protection) CAS# 6092-47-3: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 6092-47-3 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 6092-47-3 is not listed on the TSCA inventory. It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
MSDS Creation Date: 2/18/1999 Revision #2 Date: 3/18/2003 The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no way shall the company be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if the company has been advised of the possibility of such damages.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-氯乙酰氨基甲酸 在 sodium hydride 作用下， 以 乙二醇二甲醚 、 paraffin 为溶剂， 生成 2-ethoxy-oxazol-4-one
  参考文献：
  名称：

  Photochemical reactivity of keto imino ethers. VI. Type I rearrangement and (2 + 2) photocycloaddition to the carbon-nitrogen double bond of 2-oxazolin-4-ones

  摘要：

  DOI：

  10.1021/ja00858a016
• 作为产物：
  描述：

  氯乙酰氯 、 氨基甲酸乙酯 生成 N-氯乙酰氨基甲酸
  参考文献：
  名称：

  Photochemical reactivity of keto imino ethers. VI. Type I rearrangement and (2 + 2) photocycloaddition to the carbon-nitrogen double bond of 2-oxazolin-4-ones

  摘要：

  DOI：

  10.1021/ja00858a016

文献信息

• AMIDINE COMPOUND OR SALT THEREOF
  申请人：Tanikawa Tetsuya

  公开号：US20140155597A1

  公开（公告）日：2014-06-05

  The purpose of the present invention is to provide a novel compound which has an anti-fungal activity on pathogenic fungi including fungi belonging to the genus Candida , the genus Aspergillus and the genus Trichophyton and is useful as a medicinal agent. A compound represented by formula (I) (wherein A 1 represents a nitrogen atom or a group represented by formula CR 6 ; A 2 and A 3 are the same as or different from each other and independently represent a nitrogen atom or a group represented by formula CH; R 1 represents an aryl group which may be substituted by 1 to 5 substituents independently selected from a substituent group (2) or the like; R 2 and R 3 are the same as or different from each other and independently represent a hydrogen atom, a halogen atom, a C 1-6 alkyl group, a C 1-6 haloalkyl group or a C 1-6 alkoxy group; and R 4 and R 5 are the same as or different from each other and independently represent a hydrogen atom, a C 1-6 haloalkyl group, a C 1-6 alkyl group or the like) or a salt thereof is useful as an anti-fungal agent.

  本发明的目的是提供一种新颖的化合物，该化合物对包括属于念珠菌属、曲霉属和毛癣菌属的病原真菌具有抗真菌活性，并可用作药物。由公式(I) (其中A 1代表氮原子或由公式CR 6表示的基团；A 2和A 3相同或不同，独立地表示氮原子或由公式CH表示的基团；R 1表示可能由1至5个独立选自取代基组(2)的取代基取代的芳基；R 2和R 3相同或不同，独立地表示氢原子、卤素原子、C 1-6烷基、C 1-6卤代烷基或C 1-6烷氧基；R 4和R 5相同或不同，独立地表示氢原子、C 1-6卤代烷基、C 1-6烷基等)或其盐用作抗真菌剂。
• FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF
  申请人：Sakai Nozomu

  公开号：US20090137595A1

  公开（公告）日：2009-05-28

  The present invention provides a fused heterocyclic derivative having a potent kinase inhibitory activity and use thereof. A compound represented by the formula (I): wherein each symbol is as defined in the specification, except a particular compound, or a salt thereof, and a pharmaceutical agent containing the compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a cancer growth inhibitor or a cancer metastasis suppressor.

  本发明提供了一种具有强大激酶抑制活性的融合杂环衍生物及其用途。 一种由以下式（I）表示的化合物： 其中除了特定化合物或其盐外，每个符号如规范中定义，以及含有该化合物或其前药的药用剂，该化合物是激酶（VEGFR、VEGFR2、PDGFR、Raf）抑制剂，血管生成抑制剂，用于癌症的预防或治疗的药剂，癌症生长抑制剂或癌症转移抑制剂。
• Interleukin-4 gene expression inhibitors
  申请人：——

  公开号：US20040006123A1

  公开（公告）日：2004-01-08

  This invention discloses and claims a class of indole and benzo(b)thiophene derivatives for use in treating allergy, asthma, rhinitis, dermatitis, B-cell lymphomas, tumors and diseases associated with bacterial, rhinovirus or respiratory syncytial virus (RSV) infections. The compounds of this invention are defined by the Formula (I): 1 wherein X, Y, Z, R 1 , R 2 and R 3 are as defined in the specification; or a pharmaceutically acceptable salt thereof. In preferred embodiments of this invention it is also disclosed and claimed that the compounds of this invention are capable of modulating T helper (Th) cells, Th1/Th2, and thereby capable of inhibiting the transcription of interleukin-4 (IL-4) message, IL-4 release or IL-4 production.

  这项发明揭示并声明了一类吲哚和苯并(b)噻吩衍生物，用于治疗过敏、哮喘、鼻炎、皮炎、B细胞淋巴瘤、肿瘤以及与细菌、鼻病毒或呼吸道合胞病毒(RSV)感染相关的疾病。本发明的化合物由下式(I)定义： 1 其中X、Y、Z、R 1 、R 2 和R 3 如规范中所定义；或其药学上可接受的盐。在本发明的优选实施例中，还揭示并声明了本发明的化合物能够调节T辅助(Th)细胞、Th1/Th2，从而能够抑制白细胞介素-4(IL-4)信息的转录、IL-4的释放或IL-4的产生。
• Discovery of N -[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2- b ]pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1 H -pyrazole-5-carboxamide (TAK-593), a highly potent VEGFR2 kinase inhibitor
  作者：Naoki Miyamoto、Nozomu Sakai、Takaharu Hirayama、Kazuhiro Miwa、Yuya Oguro、Hideyuki Oki、Kengo Okada、Terufumi Takagi、Hidehisa Iwata、Yoshiko Awazu、Seiji Yamasaki、Toshiyuki Takeuchi、Hiroshi Miki、Akira Hori、Shinichi Imamura

  DOI：10.1016/j.bmc.2013.01.074

  日期：2013.4

  for the treatment of cancer. In this study, we describe the design, synthesis, and biological evaluation of 2-acylamino-6-phenoxy-imidazo[1,2-b]pyridazine derivatives. Hybridization of two distinct imidazo[1,2-b]pyridazines 1 and 2, followed by optimization led to the discovery of N-[5-(2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide

  血管内皮生长因子（VEGF）在肿瘤血管生成中起着重要作用，抑制其信号传导途径被认为是治疗癌症的有效治疗选择。在这项研究中，我们描述了2-酰基氨基-6-苯氧基-咪唑并[1,2- b ]哒嗪衍生物的设计，合成和生物学评估。两种不同的咪唑并[1,2- b ]哒嗪1和2杂交，然后进行优化导致发现N- [5-（2-[（环丙基羰基）氨基]咪唑并[1,2- b ]哒嗪- 6-基}氧基）-2-甲基苯基] -1,3-二甲基-1 H-吡唑-5-羧酰胺（23a（TAK-593）作为一种高效的VEGF受体2激酶抑制剂，IC 50值为0.95 nM。化合物23a以0.30 nM的IC 50强烈抑制了VEGF刺激的人脐静脉内皮细胞的增殖。激酶选择性分析显示23a抑制了血小板衍生的生长因子受体激酶以及VEGF受体激酶。在使用人肺腺癌A549细胞的小鼠异种移植模型中，口服1mg / kg的23a可以有效抑制肿瘤的生长（T
• [EN] IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS<br/>[FR] DERIVES D'IMIDAZOPYRIDINE ET D'IMIDAZOPYRIMIDINE EN TANT QU'AGENTS ANTIBACTERIENS
  申请人：WARNER LAMBERT CO

  公开号：WO2005089763A1

  公开（公告）日：2005-09-29

  Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of formula I as disclosed herein can be used in a variety of applications including use as antibacterial agents.

  公开了式I的化合物及其制备方法。进一步公开了制备式I生物活性化合物的方法，以及包含式I化合物的药用可接受组合物的方法。本文公开的式I化合物可用于各种应用，包括用作抗菌剂。